Posted on October 13, 202610/13/26
From PICO Planning to JCA Monitoring: Building Market Access Readiness in the EU JCA Era
Posted on October 5, 202610/5/26
From AI Answers to Decision-Grade Market Access
Posted on September 30, 20269/30/26
Shaping the Future of Pharmaceutical Market Access
Posted on September 23, 20269/23/26
Understanding MFN Pricing: Key Considerations for Pharma Manufacturers
Posted on August 25, 20268/25/26
The GLP-1 Tender Signal: What 238 Awarded Bids Reveal About Who’s Really Winning
Posted on July 29, 20267/29/26
The Industry Doesn’t Have an Access Collaboration Problem. It Has an Accountability Problem.
Posted on July 10, 20267/10/26
How IRA, MFN, and HTA are rewriting oncology launch strategy
Posted on June 4, 20266/4/26
Winning in the EU JCA Era: Why Proactive Intelligence Will Define Market Access Success
Posted on May 19, 20265/19/26
Your Market Access Model is Bleeding Value
Posted on May 6, 20265/6/26